The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 March 2026•

1 min read

Kamada Reports Record 2025 Results and Affirms Double-Digit Growth Outlook for 2026

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1Kamada reported record top-line and bottom-line financial results for the full year 2025.

Kamada Ltd. (NASDAQ: KMDA) announced record-breaking financial performance for the fiscal year 2025, achieving all-time highs in both revenue and profitability. The specialty biopharmaceutical company attributed its success to the strong performance of its portfolio of plasma-derived products targeting rare and serious conditions. Following these results, management reaffirmed its financial guidance for 2026, projecting continued organic growth exceeding 10%. This positive outlook reflects the company's leadership position in the niche plasma-derived therapeutics market. Investors are reacting positively to the combination of current record earnings and the sustained growth trajectory expected for the coming year. The company remains focused on expanding its market share and advancing its pipeline of specialized treatments.